Pfizer Recalls More Quinapril Due to Potential Carcinogen

The voluntary recall of five lots of the antihypertensive quinapril (Accupril) was prompted by unacceptable levels of N-nitroso-quinapril, a potential carcinogen.
Medscape Medical News

source https://www.medscape.com/viewarticle/972787?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?